Kun Cheng
Impact in
- Hepatology top 2%
- Liver physiology and pathology
- Biomaterials top 2%
- Nanoparticle-Based Drug Delivery
Papers in
-
- RNA Interference and Gene Delivery 26
- Advanced biosensing and bioanalysis techniques 14
- Oncology 22
- Pancreatic and Hepatic Oncology Research 7
- Co-authors
- Wanyi Tai (8 shared papers)Rubi Mahato (4 shared papers)Akshay Jain (16 shared papers)Zhen Zhao (19 shared papers)Hao Liu (7 shared papers)Ram I. Mahato (11 shared papers)Li Zhang (3 shared papers)Chang Liu (2 shared papers)
- Journals
- Molecular Pharmaceutics (10 papers)Journal of Controlled Release (7 papers)Pharmaceutical Research (6 papers)Advanced Therapeutics (3 papers)Nanomedicine Nanotechnology Biology and Medicine (3 papers)
- Partner nations
- United StatesChinaAustralia
In The Last Decade
Kun Cheng
99 papers receiving 4.6k citations
Kun Cheng's Hit Papers
Peers
Comparison fields: 5 of 127
- Hepatology 400
- Biomaterials 733
- Molecular Biology 2.5k
- Oncology 802
- Cancer Research 400
Countries citing papers authored by Kun Cheng
This map shows the geographic impact of Kun Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun Cheng more than expected).
Fields of papers citing papers by Kun Cheng
This network shows the impact of papers produced by Kun Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun Cheng. The network helps show where Kun Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Kun Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 102 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications Hit paper breakdown → | 2017 | 475 |
| 2 | 2010 | 465 | |
| 3 | 2011 | 310 | |
| 4 | 2016 | 239 | |
| 5 | The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA Hit paper breakdown → | 2021 | 211 |
| 6 | 2021 | 115 | |
| 7 | 2019 | 107 | |
| 8 | 2020 | 104 | |
| 9 | 2014 | 98 | |
| 10 | 2009 | 97 | |
| 11 | 2019 | 88 | |
| 12 | 2023 | 84 | |
| 13 | 2011 | 82 | |
| 14 | 2019 | 81 | |
| 15 | 2020 | 79 | |
| 16 | 2013 | 79 | |
| 17 | 2013 | 77 | |
| 18 | 2004 | 74 | |
| 19 | 2014 | 69 | |
| 20 | 2016 | 67 |
About Kun Cheng
Kun Cheng is a scholar working on Molecular Biology, Oncology, Immunology, Hepatology and Surgery, having authored 102 papers that have together received 4.7k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (26 papers), Liver physiology and pathology (15 papers), Advanced biosensing and bioanalysis techniques (14 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Pancreatic and Hepatic Oncology Research (7 papers), Immunotherapy and Immune Responses (6 papers), Pancreatic function and diabetes (6 papers) and MicroRNA in disease regulation (6 papers). The work is most often cited by research in Hepatology (400 citations), Biomaterials (733 citations), Molecular Biology (2.5k citations), Oncology (802 citations) and Cancer Research (400 citations). Kun Cheng has collaborated with scholars based in United States, China and Australia. Frequent co-authors include Wanyi Tai, Rubi Mahato, Akshay Jain, Zhen Zhao, Hao Liu, Ram I. Mahato, Li Zhang, Chang Liu, Ashutosh Barve and Bin Qin. Their work appears in journals such as Molecular Pharmaceutics, Journal of Controlled Release, Pharmaceutical Research, Advanced Therapeutics and Nanomedicine Nanotechnology Biology and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.